AZD4144 + Placebo

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sepsis

Conditions

Sepsis, Acute Kidney Injury

Trial Timeline

Feb 10, 2026 → Feb 11, 2027

NCT ID

NCT07215702

About AZD4144 + Placebo

AZD4144 + Placebo is a phase 2 stage product being developed by AstraZeneca for Sepsis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07215702. Target conditions include Sepsis, Acute Kidney Injury.

What happened to similar drugs?

9 of 19 similar drugs in Sepsis were approved

Approved (9) Terminated (1) Active (9)

✅MeropenemPfizerApproved

✅ImipenemMerckApproved

✅Drotrecogin Alfa (activated)Eli LillyApproved

✅Drotrecogin alfa (activated)Eli LillyApproved

✅Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved

✅drotrecogin alfa (activated)Eli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07215702	Phase 2	Recruiting	Feb 10, 2026	Feb 11, 2027	Sepsis
NCT06942923	Phase 1	Completed	Apr 22, 2025	Sep 29, 2025	Healthy Participants

Competing Products

20 competing products in Sepsis

See all competitors

Product	Company	Stage	Hype Score
Alkaline Phosphatase + Placebo	AM-Pharma	Phase 2	25
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	35
Meropenem	Pfizer	Approved	43
Imipenem	Merck	Approved	39
Cefiderocol	Shionogi	Phase 1	29
eritoran tetrasodium + Placebo	Eisai	Phase 3	40
E5564	Eisai	Phase 2	35
Drotrecogin Alfa (Activated) + placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin Alfa (activated)	Eli Lilly	Approved	43
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
sPLA2 Inhibitor	Eli Lilly	Phase 1/2	32
Drotrecogin alfa (activated)	Eli Lilly	Approved	43
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
AZD9773 (CytoFab)	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35